

KLK-1, His Human

Catalog # PVGS1145

Product Information	
Species	Human
Sequence	MWFLVLCLAL SLGGTGAAPP IQSRIVGGWE CEQHSQPWQA ALYHFSTFQC GGILVHRQWV LTAAHCISDN YQLWLGRHNL FDDENTAQFV HVSESFPHPG FNMSLLENHT RQADEDYSHD LMLLRLTEPA DTITDAVKVV ELPTEEPEVG STCLASGWGS IEPENFSFPD DLQCVDLKIL PNDECKKAHV QKVTDFMLCV GHLEGGKDTC VGDSGGPLMC DGVLQGVTSW GYVPCGTPNK PSVAVRVLSY VKWIEDTIAE NSHHHHHH
Purity	>95% by SDS-PAGE and HPLC analyses.
Endotoxin Level	Less than 1 EU/ Ig of rHuKLK-1, His as determined by LAL method.
Formulation Reconstitution	Lyophilized from a 0.2 Im filtered concentrated solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.

Additional Information

Target BackgroundKallikreins are members of a highly conserved serine proteases that are
involved in the post-translational modification of many polypeptides, and
plays a role in diverse physiological processes. Fifteen kallikreins who seen
coding genes are located in a cluster on chromosome 19 have been reported,
and growing evidence suggests that many kallikreins are implicated in
carcinogens is and some have potential as novel cancer and other disease
biomakers. Human kallikrein1(KLK1), also known as tissue kallikrein, is
functionally conserved in its capacity to cleave the low molecular weight
kininogen to release the vasoactive peptide, Lys-bradykinin which plays a role
in regulating vasodilation, blood pressure reduction, smooth muscle
relaxation and contraction, pain induction and inflammation.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.